Abstract:Background:some study has been confirmed more HLA dispariety between donor and patients has a stronger anti‐leukemia effect acute leukemia in some subgroupAims:To identified whether haploidentical donor(HID) have better graft‐versus‐leukemia effects than matched unrelated donor(MUD) and Identical sibling donors(ISD) in allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in complete remission(CR).Methods:With this background, Between April 2012 and December 2016, consecutive 480 patients with AML in complete remission(CR) who underwent allogeneic HSCT in our center were analyzed retrospectively. donor sources were HID in 316 (65.8%) cases. MUD in 78(16.2%)cases,ISD in 86(17.9%) cases. The median age was 23(range,1.1 to 65) years. Male to female was 263: 217. The median disease course was 8 (range,2 to 57) months. 368(76.6%) cases transplant at CR1 and 112(23.3%) patients at CR2. according to cytogenetic risk stratification,83(17.2%) in poor risk,264(55.0%) in intermediate risk,133(27.7%) in favourable risk.64(13.3%) patients with FLT3‐ITD.Myeloablative conditioning regimens were administered with either Busulfan (Bu) plus Cyclophosphamide (Cy)/Fludarabine (Flu)‐based in 449(93.5%) patients or total body irradiation (TBI) plus Cy/Flu in 31 (6.4%) patients. Antithymocyte globulin was used in MUD and HID‐HSCT. unmanipulated bone marrow(BM) and peripheral blood stem cells (PBSC) for ISD and HID HSCT,only PBSC for MUD transplant were applied as the grafts. GVHD prophylaxis included mycophenolate mofetil(MMF), cyclosporine‐A with short‐term methotrexate for HID and MUD‐HSCT. MMF are not included in ISD‐HSCT.Results:The survivor median follow‐up time were 38(18–74)months, there were similar 5‐year OS (74.7 ± 3.0% vs 86.0 ± 4.3% vs 77.9 ± 4.5%,P = 0.497) and DFS (74.1 ± 3.0% vs 76.6 ± 7.0% vs 76.7 ± 4.6%, P = 0.729)among HID,MUD,ISD‐cohorts.there were no difference relapse(14.3 ± 2.9%vs11.8 ± 7.1%vs9.2 ± 3.3%,P = 0.857) and NRM (13.2 ± 2.0%vs5.3 ± 3.2% vs13.2 ± 2.0%,P = 0.695) among three donor type. We performed univariate analysis the impact of donor type on OS and LFS,relapse in patients at each disease stage such as: patients age(≤18y or 19–40y or>40y), white blood cell at diagnosis (<50 × 109/L or ≥50 × 109/L),cause of disease (primary or sencodary),cytogenetics risk stratification (low or intermediate or high), FLT3‐ITD (with or none),NCCN risk stratification(low or intermediate or high),CRstatus(CR1or CR2),MRD(negative or positive), Extramedullary lesions (with or none), we found no significant differences in OS,LFS,relapse due to donor type. performed multivariate analysis for all patients of pretransplantation variables showed secondary AML, MRD positive were two adverse factor related to OS. MRD positive, HCT‐CI ≥2 were two risk factor associated to DFS. the patients with MRD positive,disease status in CR2,NCCN in higher risk, HCT‐CI ≥2 were associated with cumulative incidence of relapse(CIR).the patients age over 40‐y was only risk factor related to TRM.Summary/Conclusion:HID‐HSCT compared to MUD and ISD had similar graft verse leukemia effect on allo‐HSCT for AML in CR status and on its each disease stage.

Similar Incidence of Severe Acute GVHD and Less Severe Chronic GVHD in PBSCT from Unmanipulated, Haploidentical Donors Compared with That from Matched Sibling Donors for Patients with Haematological Malignancies.

Superior Graft-Versus-leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-identical Sibling Donor Grafts for High-Risk Acute Leukemia: an Historic Comparison.

Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors

Role of Antithymocyte Globulin in Matched Sibling Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

Haploidentical vs. mismatched unrelated donor transplants with posttransplant cyclophosphamide-based GVHD prophylaxis

Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide As an Effective Regimen for Prophylaxis of Graft Versus Host Disease after Haploidentical Peripheral Blood Stem Cell Transplantation with Maternal/Collateral Related Donors

Comparison of Unrelated Cord Blood Transplantation and HLA-identical Sibling Peripheral Blood Stem Cell Transplantation for the Treatment of Adult Hematological Malignancies

Impact of Lymphocyte Subsets of Grafts on the Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation

Low-dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide As Graft-Versus-host Disease Prophylaxis in Haploidentical Peripheral Blood Stem Cell Transplantation Combined with Unrelated Cord Blood for Patients with Hematologic Malignancies: a Prospective, Phase II Study

Peripheral Blood Stem Cell Transplantation from Haploidentical Related Donor Could Achieve Satisfactory Clinical Outcomes for Intermediate- or High-Risk Adult Acute Myeloid Leukemia Patients.

PF274 UNMANIPULATED HID COMPARED TO MUD AND ISD HAD SIMILAR GRAFT ANTI‐LEUKEMIA EFFECT ON MYELOABLATIVE HSCT FOR AML IN CR

Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors

Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation-A Matched-Pair Analysis

Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study

Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation

Prognoses and Complications of Patients with Hematological Malignancies after Haploidentical or Siblingidentical Donor Stem Cell Transplantations

Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry

Long-Term Outcomes of Unmanipulated Haploidentical Hsct for Paediatric Patients with Acute Leukaemia

Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.

The Inferiority of G-PB to Rhg-Csf-mobilized Blood and Marrow Grafts As a Stem Cell Source in Patients with High-Risk Acute Leukemia Who Underwent Unmanipulated HLA-mismatched/haploidentical Transplantation: a Comparative Analysis